Histamine dihydrochloride (Ceplene®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000355
English
Authors' recommendations:
Histamine dihydrochloride (Ceplene®) is not recommended for use within NHS Wales for maintenance therapy for adult patients with acute myeloid leukaemia in accordance with its licensed indication. The case for clinical effectiveness and cost effectiveness has not been proven.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=181568&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Histamine
- Leukemia, Myeloid, Acute
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.